Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

62 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Bortezomib-releasing silica-collagen xerogels for local treatment of osteolytic bone- and minimal residual disease in multiple myeloma.
Hose D, Ray S, Rößler S, Thormann U, Schnettler R, de Veirman K, El Khassawna T, Heiss C, Hild A, Zahner D, Alagboso F, Henss A, Beck S, Emde-Rajaratnam M, Burhenne J, Bamberger J, Menu E, de Bruyne E, Gelinsky M, Kampschulte M, Rohnke M, Wenisch S, Vanderkerken K, Hanke T, Seckinger A, Alt V. Hose D, et al. Among authors: de veirman k. J Hematol Oncol. 2024 Dec 18;17(1):128. doi: 10.1186/s13045-024-01636-4. J Hematol Oncol. 2024. PMID: 39695697 Free PMC article.
Fueling CARs: metabolic strategies to enhance CAR T-cell therapy.
Van der Vreken A, Vanderkerken K, De Bruyne E, De Veirman K, Breckpot K, Menu E. Van der Vreken A, et al. Among authors: de veirman k. Exp Hematol Oncol. 2024 Jul 10;13(1):66. doi: 10.1186/s40164-024-00535-1. Exp Hematol Oncol. 2024. PMID: 38987856 Free PMC article. Review.
AXL-specific single domain antibodies show diagnostic potential and anti-tumor activity in Acute Myeloid Leukemia.
Vandewalle N, Satilmis H, Verheye E, Fan R, Wang Y, De Groof TWM, Bridoux J, Kerre T, De Beule N, De Becker A, De Bruyne E, Menu E, Vanderkerken K, Breckpot K, Devoogdt N, De Veirman K. Vandewalle N, et al. Among authors: de veirman k. Theranostics. 2024 Apr 15;14(7):2656-2674. doi: 10.7150/thno.91456. eCollection 2024. Theranostics. 2024. PMID: 38773967 Free PMC article.
Scrutiny of chimeric antigen receptor activation by the extracellular domain: experience with single domain antibodies targeting multiple myeloma cells highlights the need for case-by-case optimization.
Hanssens H, Meeus F, De Vlaeminck Y, Lecocq Q, Puttemans J, Debie P, De Groof TWM, Goyvaerts C, De Veirman K, Breckpot K, Devoogdt N. Hanssens H, et al. Among authors: de veirman k. Front Immunol. 2024 Apr 19;15:1389018. doi: 10.3389/fimmu.2024.1389018. eCollection 2024. Front Immunol. 2024. PMID: 38720898 Free PMC article.
Targeting S100A9 protein affects mTOR-ER stress signaling and increases venetoclax sensitivity in Acute Myeloid Leukemia.
Fan R, Satilmis H, Vandewalle N, Verheye E, De Bruyne E, Menu E, De Beule N, De Becker A, Ates G, Massie A, Kerre T, Törngren M, Eriksson H, Vanderkerken K, Breckpot K, Maes K, De Veirman K. Fan R, et al. Among authors: de veirman k. Blood Cancer J. 2023 Dec 18;13(1):188. doi: 10.1038/s41408-023-00962-z. Blood Cancer J. 2023. PMID: 38110349 Free PMC article.
RNA-sequencing based first choice of treatment and determination of risk in multiple myeloma.
Emde-Rajaratnam M, Beck S, Benes V, Salwender H, Bertsch U, Scheid C, Hänel M, Weisel K, Hielscher T, Raab MS, Goldschmidt H, Jauch A, Maes K, De Bruyne E, Menu E, De Veirman K, Moreaux J, Vanderkerken K, Seckinger A, Hose D. Emde-Rajaratnam M, et al. Among authors: de veirman k. Front Immunol. 2023 Nov 15;14:1286700. doi: 10.3389/fimmu.2023.1286700. eCollection 2023. Front Immunol. 2023. PMID: 38035078 Free PMC article.
62 results